Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy

Vaccine

Volumn 26, Issue 52, 2008, Pages 6883-6893

  Greenough, Thomas C ^a   Cunningham, Coleen K ^b   Muresan, Petronella ^c   McManus, Margaret ^a   Persaud, Deborah ^d   Fenton, Terry ^c   Barker, Piers ^b   Gaur, Aditya ^e   Panicali, Dennis ^f   Sullivan, John L ^a   Luzuriaga, Katherine ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f Therion Biologics Corporation   (United States)

Author keywords

HIV 1; Therapeutic immunization; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; RECOMBINANT VACCINE; VIRUS VECTOR;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CARDIOTOXICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; MALE; PRIORITY JOURNAL; VIRUS REPLICATION;

ADOLESCENT; AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CYTOKINES; FEMALE; FLOW CYTOMETRY; FOWLPOX VIRUS; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; MALE; PROSPECTIVE STUDIES; RNA, VIRAL; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VACCINIA; YOUNG ADULT;

EID: 56649097350     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.084     Document Type: Article

References (31)

1. Dorrell L., Williams P., Suttill A., Brown D., Roberts J., Conlon C., et al. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 25 17 (2007) 3277-3283
2. Kennedy J.S., Frey S.E., Yan L., Rothman A.L., Cruz J., Newman F.K., et al. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis 190 7 (2004) 1286-1294
3. McCurdy L.H., Larkin B.D., Martin J.E., and Graham B.S. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis 38 12 (2004) 1749-1753
4. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93 21 (1996) 11341-11348
5. Paoletti E., Taylor J., Meignier B., Meric C., and Tartaglia J. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev Biol Stand 84 (1995) 159-163
6. Parrino J., McCurdy L.H., Larkin B.D., Gordon I.J., Rucker S.E., Enama M.E., et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25 8 (2007) 1513-1525
7. Plotkin S.A., Cadoz M., Meignier B., Meric C., Leroy O., Excler J.L., et al. The safety and use of canarypox vectored vaccines. Dev Biol Stand 84 (1995) 165-170
8. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schafer H., and Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's translation). Dtsch Med Wochenschr 99 47 (1974) 2386-2392
9. Harrer E., Bauerle M., Ferstl B., Chaplin P., Petzold B., Mateo L., et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 10 2 (2005) 285-300
10. Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24 15 (2006) 3026-3034
11. Jager E., Karbach J., Gnjatic S., Neumann A., Bender A., Valmori D., et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 103 39 (2006) 14453-14458
12. Anderson R.J., Hannan C.M., Gilbert S.C., Laidlaw S.M., Sheu E.G., Korten S., et al. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol 172 5 (2004) 3094-3100
13. Im E.J., Nkolola J.P., di Gleria K., McMichael A.J., and Hanke T. Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. Eur J Immunol 36 10 (2006) 2574-2584
14. Casey C.G., Iskander J.K., Roper M.H., Mast E.E., Wen X.J., Torok T.J., et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 294 21 (2005) 2734-2743
15. da Silva M., Coderre J., Sullivan J.L., Lifson J., and Greenough T. Quantitation of CD4 and CD8 T-cell proliferation to soluble antigens and inactivated HIV-1 by flow cytometry in various stages of disease. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington (2002)
16. Buseyne F., Le Gall S., Boccaccio C., Abastado J.P., Lifson J.D., Arthur L.O., et al. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat Med 7 3 (2001) 344-349
17. Terajima M., Cruz J., Raines G., Kilpatrick E.D., Kennedy J.S., Rothman A.L., et al. Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 197 7 (2003) 927-932
18. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204 6 (2007) 1405-1416
19. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. In: Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W., and Coico R. (Eds). Current Protocols in Immunology (2004), John Wiley & Sons 12.11.1-12.11.15
20. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79 16 (2005) 10103-10107
21. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22 1 (2003) 21-29
22. Kalams S.A., Buchbinder S.P., Rosenberg E.S., Billingsley J.M., Colbert D.S., Jones N.G., et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 73 8 (1999) 6715-6720
23. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278 5342 (1997) 1447-1450
24. Kapogiannis B.G., Henderson S.L., Nigam P., Sharma S., Chennareddi L., Herndon J.G., et al. Defective IL-2 production by HIV-1-specific CD4 and CD8 T cells in an adolescent/young adult cohort. AIDS Res Hum Retroviruses 22 3 (2006) 272-282
25. Keefer M.C., Elizaga M., Ferrari G., Metch B., Panicali D., Cardinali M., et al. Safety and immunogenicity of rMVA-HIV and rFowlpox (FPV)-HIV vaccines, alone or in combination, in healthy vaccinia-naïve HIV-1 negative participants. AIDS Vaccine 2007. Seattle, WA (2007)
26. Dorrell L., Yang H., Ondondo B., Dong T., di Gleria K., Suttill A., et al. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 80 10 (2006) 4705-4716
27. Harari A., Bart P.A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205 1 (2008) 63-77
28. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 205 1 (2008) 7-12
29. Ondondo B.O., Yang H., Dong T., di Gleria K., Suttill A., Conlon C., et al. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur J Immunol 36 10 (2006) 2585-2594
30. Hawkridge T., Scriba T.J., Gelderbloem S., Smit E., Tameris M., Moyo S., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis. 198 4 (2008) 544-552
31. Imoukhuede E.B., Berthoud T., Milligan P., Bojang K., Ismaili J., Keating S., et al. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Vaccine 24 42-43 (2006) 6526-6533